

CENTER FOR DISEASE CONTROL

# BIOLOGICS

SURVEILLANCE

REPORT NO. 45

APRIL, MAY, JUNE, 1970



COOPERATING IN THIS PROGRAM ARE THE FOLLOWING:

Cutter Laboratories

The Dow Chemical Company

Hyland Laboratories

Illinois Department of Public Health

Lederle Laboratories

Eli Lilly and Company

Massachusetts Department of Public Health

Merck Sharp & Dohme

Michigan Department of Health

The National Drug Company

Parke, Davis & Company

Pfizer Laboratories

The Philadelphia Blood Center

Philips Roxane, Inc.

Smith Kline & French Laboratories

E. R. Squibb & Sons, Inc.

Texas State Department of Health

Wyeth Laboratories

Center for Disease Control

Advisory Committee on  
Immunization Practices

Biologics Surveillance

David J. Sencer, M. D., Director

John J. Witte, M. D.  
Secretary, A.C.I.P.  
Chief, Immunization Branch  
State & Community Services Division, CDC

William W. Dyal  
Immunization Branch  
State & Community Services Division, CDC

## BIOLOGICS SURVEILLANCE

This summary is intended primarily for those concerned with the national use and application of immunizing agents. Although the "Net Distribution" figures are recognized as representing rough approximations only, we believe that a continuing analysis of this kind, interpreted in the light of national and local immunization surveys, will aid in assessing the overall immunization status of the population. It is anticipated that a knowledge of utilization and inventory data will assist in foreseeing possible critical shortages in vaccine supply.

Each major antigen is represented in the form of a line graph showing "Estimated Net Distribution" for the previous year and through the above month in 1970. Estimated Net Distribution represents doses of each vaccine distributed for use during the reporting period and is depicted as gross sales or distribution less recordable returned doses. In addition, specific data is tabulated for each antigen reported during this quarter and is cumulated from the first of the year until present time. Civilian and military data have been combined.

To maintain confidentiality of an individual commercial manufacturer's report for economic and production reasons, current tabulations are available only when at least three producers market and report figures for essentially the same product. This is a basic agreement of the Biologics Surveillance program.

In some instances, where adequate time has elapsed since production and distribution, manufacturers have allowed the data to be released when not all the criteria of confidentiality could be met. Addition of these data to the summaries completes the "natural history" of early patterns of vaccine utilization.

**MONTHLY BIOLOGIC SUMMARY FOR APRIL 1970**

LINE NO.	PRODUCT DESCRIPTION	A* GROSS NO. OF DOSES SOLD OR DISTRIBUTED THIS MONTH	D NO. OF DOSES RETURNED DURING MONTH	E* NET NO. OF DOSES SOLD OR DISTRIBUTED THIS MONTH	B* NO. OF FINISHED DOSES READY FOR IMMEDIATE SHIPMENT AT MONTH END	C NO. OF FINISHED DOSES NOT READY FOR IMMEDIATE SHIPMENT
1-	Influenza Virus Vaccine (if applicable, specify type) Monovalent	<b>60</b>	<b>15,010</b>	<b>-14,950</b>	<b>25,350</b>	
	Bivalent	<b>10,780</b>	<b>112,005</b>	<b>-101,225</b>	<b>1,194,540</b>	<b>311,955</b>
	Polyvalent	<b>**</b>	<b>**</b>	<b>**</b>	<b>**</b>	<b>**</b>
2.	Diphtheria Toxoid with Tetanus Toxoid (Pediatric)	<b>197,508</b>	<b>39,455</b>	<b>158,053</b>	<b>950,616</b>	<b>557,643</b>
3.	Diphtheria and Tetanus Toxoids with Pertussis Vaccine	<b>1,519,707</b>	<b>109,030</b>	<b>1,410,667</b>	<b>2,285,401</b>	<b>1,115,894</b>
4.	Tetanus Toxoid with Diphtheria Toxoid (Adult)	<b>523,840</b>	<b>8,040</b>	<b>515,800</b>	<b>1,756,730</b>	<b>578,562</b>
5.	Diphtheria Toxoid	<b>**</b>	<b>**</b>	<b>**</b>	<b>**</b>	<b>**</b>
6.	Tetanus Toxoid	<b>1,521,687</b>	<b>117,372</b>	<b>1,404,315</b>	<b>7,131,701</b>	<b>1,640,702</b>
7.	Pertussis Vaccine	<b>10,200</b>	<b>1,845</b>	<b>8,355</b>	<b>26,955</b>	
8.	Diphtheria-Tetanus Toxoids and Poliomyelitis Vaccine Combined: Diphtheria-Tetanus Toxoids and Pertussis and Poliomyelitis Vaccines Combined	<b>**</b>	<b>**</b>	<b>**</b>	<b>**</b>	<b>**</b>
9.	Poliomyelitis Vaccine (Inactivated)	<b>**</b>	<b>**</b>	<b>**</b>	<b>**</b>	<b>**</b>
10.	Poliomyelitis Vaccine, Live, Oral, Type 1	<b>41,010</b>	<b>8,182</b>	<b>32,828</b>	<b>109,170</b>	
	Type 2	<b>39,924</b>	<b>919</b>	<b>39,005</b>	<b>307,406</b>	<b>30,631</b>
	Type 3	<b>25,070</b>	<b>725</b>	<b>24,345</b>	<b>99,285</b>	
11.	Poliomyelitis Vaccine, Live, Oral, Trivalent	<b>1,662,345</b>	<b>10,560</b>	<b>1,651,785</b>	<b>5,902,045</b>	
12.	Measles Virus Vaccine, Live, Attenuated	<b>412,608</b>	<b>37,984</b>	<b>374,624</b>	<b>558,734</b>	
13.	Smallpox Vaccine	<b>1,112,653</b>	<b>60,688</b>	<b>1,051,965</b>	<b>3,175,381</b>	<b>19,847,363</b>
14.	Rabies Vaccine	<b>51,884</b>	<b>1,048</b>	<b>50,836</b>	<b>47,941</b>	<b>77,808</b>
15.	Immune Serum Globulin (Human)	<b>555,238</b> cc	<b>20,332</b> cc	<b>534,906</b> cc	<b>1,100,106</b> cc	<b>329,906</b> cc
	Measles Immune Globulin (Human)	<b>**</b> cc	<b>**</b> cc	<b>**</b> cc	<b>**</b> cc	<b>**</b> cc
	Poliomyelitis Immune Globulin (Human)	<b>**</b> cc	<b>**</b> cc	<b>**</b> cc	<b>**</b> cc	<b>**</b> cc
	Tetanus Immune Globulin (Human)	<b>99,620</b> cc	<b>481</b> cc	<b>99,139</b> cc	<b>763,327</b> cc	<b>69,872</b> cc
16.						
17.						

\*COLUMN E IS COLUMN A LESS COLUMN D OR NET DOSES DISTRIBUTED; COLUMNS A AND B INCLUDE DOMESTIC AND MILITARY.

\*\*NOT SHOWN SINCE LESS THAN THREE PRODUCERS REPORTED.

**MONTHLY BIOLOGIC SUMMARY FOR MAY 1970**

LINE NO.	PRODUCT DESCRIPTION	A* GROSS NO. OF DOSES SOLD OR DISTRIBUTED THIS MONTH	D NO. OF DOSES RETURNED DURING MONTH	E* NET NO. OF DOSES SOLD OR DISTRIBUTED THIS MONTH	B* NO. OF FINISHED DOSES READY FOR IMMEDIATE SHIPMENT AT MONTH END	C NO. OF FINISHED DOSES NOT READY FOR IMMEDIATE SHIPMENT
1-	Influenza Virus Vaccine (if applicable, specify type) Monovalent	**	**	**	**	**
	Bivalent	4,405	83,965	-79,560	1,514,285	1,148,975
	Polyvalent	**	**	**	**	**
2.	Diphtheria Toxoid with Tetanus Toxoid (Pediatric)	197,482	34,505	162,977	772,394	757,623
3.	Diphtheria and Tetanus Toxoids with Pertussis Vaccine	1,392,604	96,235	1,296,369	3,130,828	834,846
4.	Tetanus Toxoid with Diphtheria Toxoid (Adult)	452,820	13,500	439,320	2,416,380	471,704
5.	Diphtheria Toxoid	**	**	**	**	**
6.	Tetanus Toxoid	1,502,582	74,634	1,427,948	5,041,707	1,889,025
7.	Pertussis Vaccine	9,820	720	9,100	17,105	
8.	Diphtheria-Tetanus Toxoids and Poliomyelitis Vaccine Combined: Diphtheria-Tetanus Toxoids and Pertussis and Poliomyelitis Vaccines Combined	**	**	**	**	**
9.	Poliomyelitis Vaccine (Inactivated)	**	**	**	**	**
10.	Poliomyelitis Vaccine, Live, Oral, Type 1	23,662	4,785	18,877	121,774	
	Type 2	33,932	771	33,161	270,112	30,631
	Type 3	22,260	430	21,830	164,875	
11.	Poliomyelitis Vaccine, Live, Oral, Trivalent	3,339,060	17,650	3,321,410	6,174,560	
12.	Measles Virus Vaccine, Live, Attenuated	350,822	25,622	325,200	1,110,529	1,674,099
13.	Smallpox Vaccine	1,300,045	64,571	1,235,474	2,707,888	19,684,867
14.	Rabies Vaccine	49,494	1,308	48,186	46,474	163,112
15.	Immune Serum Globulin (Human)	537,582 cc	15,894 cc	521,688 cc	1,097,018 cc	334,270 cc
	Measles Immune Globulin (Human)	** cc	** cc	** cc	** cc	** cc
	Poliomyelitis Immune Globulin (Human)	** cc	** cc	** cc	** cc	** cc
	Tetanus Immune Globulin (Human)	160,018 cc	319 cc	159,699 cc	655,975 cc	119,236 cc
16.	Live Rubella Virus Vaccine <sup>(1)</sup>	18,794,741	11,500	18,783,241	2,761,500	5,028,000
17.						

\*COLUMN E IS COLUMN A LESS COLUMN D OR NET DOSES DISTRIBUTED; COLUMNS A AND B INCLUDE DOMESTIC AND MILITARY.

\*\*NOT SHOWN SINCE LESS THAN THREE PRODUCERS REPORTED.

HSM 4.206A (NCDC) 2-69

(1) figures from licensure through May 1970

**MONTHLY BIOLOGIC SUMMARY FOR JUNE 1970**

LINE NO.	PRODUCT DESCRIPTION	A* GROSS NO. OF DOSES SOLD OR DISTRIBUTED THIS MONTH	D NO. OF DOSES RETURNED DURING MONTH	E* NET NO. OF DOSES SOLD OR DISTRIBUTED THIS MONTH	B* NO. OF FINISHED DOSES READY FOR IMMEDIATE SHIPMENT AT MONTH END	C NO. OF FINISHED DOSES NOT READY FOR IMMEDIATE SHIPMENT
1-	Influenza Virus Vaccine (if applicable, specify type) Monovalent	**	**	**	**	**
	Bivalent	1,600,965	90,195	1,510,770	1,563,110	1,296,289
	Polyvalent	**	**	**	**	**
2.	Diphtheria Toxoid with Tetanus Toxoid (Pediatric)	237,148	73,125	164,023	908,291	570,260
3.	Diphtheria and Tetanus Toxoids with Pertussis Vaccine	1,250,630	140,845	1,109,785	2,369,959	636,615
4.	Tetanus Toxoid with Diphtheria Toxoid (Adult)	811,730	22,260	789,470	2,149,700	623,044
5.	Diphtheria Toxoid	**	**	**	**	**
6.	Tetanus Toxoid	1,945,802	151,454	1,794,348	6,552,625	1,205,035
7.	Pertussis Vaccine	7,390	1,500	5,890	9,715	7,930
8.	Diphtheria-Tetanus Toxoids and Poliomyelitis Vaccine Combined: Diphtheria-Tetanus Toxoids and Pertussis and Poliomyelitis Vaccines Combined	**	**	**	**	**
9.	Poliomyelitis Vaccine (Inactivated)	**	**	**	**	**
10.	Poliomyelitis Vaccine, Live, Oral, Type 1	503,390	4,074	499,316	136,779	
	Type 2	40,396	993	39,403	260,401	63,542
	Type 3	290,933	555	290,378	174,810	
11.	Poliomyelitis Vaccine, Live, Oral, Trivalent	2,076,200	18,930	2,057,270	6,460,990	
12.	Measles Virus Vaccine, Live, Attenuated	630,297	31,182	599,115	1,449,056	1,316,004
13.	Smallpox Vaccine	1,223,097	122,341	1,100,756	2,715,486	17,100,288
14.	Rabies Vaccine	90,326	946	89,380	84,013	266,963
15.	Immune Serum Globulin (Human)	472,012 cc	17,880 cc	454,132 cc	1,046,226 cc	217,484 cc
	Measles Immune Globulin (Human)	** cc	** cc	** cc	** cc	** cc
	Poliomyelitis Immune Globulin (Human)	** cc	** cc	** cc	** cc	** cc
	Tetanus Immune Globulin (Human)	150,495 cc	674 cc	149,821 cc	518,605 cc	73,380 cc
16.	Live Rubella Virus Vaccine	1,106,786	232,328	874,458	9,657,951	5,028,000
17.						

\*COLUMN E IS COLUMN A LESS COLUMN D OR NET DOSES DISTRIBUTED; COLUMNS A AND B INCLUDE DOMESTIC AND MILITARY.

\*\*NOT SHOWN SINCE LESS THAN THREE PRODUCERS REPORTED.

## DISTRIBUTION OF BIOLOGICS – UNITED STATES, 1970

Biologics	Net Total Doses	
	April through June 1970	January through June 1970
Influenza Virus Vaccine (Monovalent)	**	**
Influenza Virus Vaccine (Polyvalent)	**	**
Influenza Virus Vaccine (Bivalent)	1,329,985	1,117,275
Diphtheria Toxoid	**	**
Pertussis Vaccine	23,345	53,200
Tetanus Toxoid	4,626,611	7,951,331
Poliomyelitis Vaccine*	**	**
Poliovirus Vaccine, Live, Oral, Type 1	551,021	588,404
Poliovirus Vaccine, Live, Oral, Type 2	111,569	219,088
Poliovirus Vaccine, Live, Oral, Type 3	336,553	409,903
Poliovirus Vaccine, Live, Oral, Trivalent	7,030,465	11,446,608
Measles Virus Vaccine, Live, Attenuated	1,298,939	2,205,414
Smallpox Vaccine	3,388,195	7,570,908
Rabies Vaccine	188,402	339,597
Immune Serum Globulin (Human)	1,510,726	3,306,812
Poliomyelitis Immune Globulin (Human)	**	**
Tetanus Immune Globulin (Human)	408,659	504,012
Live Rubella Virus Vaccine	19,657,699 <sup>(1)</sup>	19,657,699 <sup>(1)</sup>

\*Inactivated (Salk Type)

<sup>(1)</sup> Vaccine distributed from licensure through June 1970


## DISTRIBUTION OF COMBINED BIOLOGICS – UNITED STATES, 1970

Biologics	Net Total Doses	
	April through June 1970	January through June 1970
Diphtheria and Tetanus Toxoids Combined	485,053	819,322
Diphtheria and Tetanus Toxoids and Pertussis Vaccine Combined	3,816,821	8,845,523
Tetanus and Diphtheria Toxoids Combined (For Adult Use)	1,744,590	3,103,290
Diphtheria and Tetanus Toxoids and Poliomyelitis Vaccine; Diphtheria and Tetanus Toxoids and Pertussis and Poliomyelitis Vaccines	**	**

\*\*Not shown since fewer than three producers reported

Figure 1.

DIPHTHERIA AND TETANUS TOXOIDS, PERTUSSIS VACCINE  
UNITED STATES\* (Net Distribution by Month)



\*INCLUDES ALL PRODUCTS CONTAINING THESE ANTIGENS



Figure 2.

POLIOVIRUS VACCINES, LIVE, ORAL-UNITED STATES,  
(Net Distribution by Month)




Figure 3.

MEASLES VIRUS VACCINE, LIVE ATTENUATED  
UNITED STATES  
(Net Distribution by Month)





Figure 4.


SMALLPOX VACCINE - UNITED STATES  
(Net Distribution by Month)



*Figure 5.*


**INFLUENZA VIRUS VACCINE · UNITED STATES\***

(Net Distribution by Month)




\* INCLUDES ALL PRODUCTS CONTAINING INFLUENZA VACCINE

*Figure 6.*  
RABIES VACCINE · UNITED STATES  
(Net Distribution by Month)



*Figure 7.*

**IMMUNE SERUM GLOBULINS (HUMAN)  
UNITED STATES**  
(Net Distribution by Month)



*Figure 8.*

**TETANUS IMMUNE GLOBULIN (HUMAN)  
UNITED STATES**  
(Net Distribution by Month)

